Abstract
The aim of this study was twofold. Firstly to assess the post treatment predictive value of various biochemical and immunological tests for early hypothyroidism after 131I therapy for Graves' disease, and secondly to determine whether or not pretreatment with Carbimazole protects against post treatment hypothyroidism. The early changes observed in serum T3, T4, TSH, thyroid microsomal and thyroglobulin antibody levels were found to be of no predictive value. A sharp rise, around 2 months, in TRAb levels following 131I therapy indicated that hypothyroidism was likely to occur. This rise was thought to reflect a greater degree of thyroid damage. Lower levels of thyroglobulin in patients who had become hypothyroid by 12 months after treatment would support this view. Five weeks Carbimazole pretreatment in this relatively small group of patients did not appear to protect against hypothyroidism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Atkinson S, McGregor AM, Kendall-Taylor P, Peterson MM, Smith BR (1982) Effect of radioiodine on stimulating activity of Graves' immunoglobulins. Clin Endocrinol 16:537–543
Bech K, Madsen SN (1980) Influence of treatment with radioiodine and propylthiouracil on thyroid stimulating immunoglobulins in Graves' disease. Clin Endocrinol 13:417–429
Black EG, Gimlette TMD, Maisey MN, Cassoni A, Harmer CL, Oates GD (1981) Serum thyroglobulin in thyroid cancer. Lancet ii:443–445
Black EG, Hoffenberg R (1983) Should one measure serum thyroglobulin in the presence of anti-thyroglobulin antibodies? Clin Endocrinol 19:597–601
Burke G, Silvester GE (1969) Hypothyroidism after treatment with sodium iodide 131I. JAMA 210:1051–1058
Crooks J, Buchanan W, Wayne EJ, Macdonald E (1960) Clinical effects of pretreatment with Methylthiouracil on results of 131I therapy. Br Med J 1:151–154
Goolden AWG, Fraser TR (1969) The effect of pretreatment with Carbimazole in patients with thyrotoxicosis subsequently treated with radioactive iodine. Br Med J 11:443–444
Hoffman DA (1984) Late effects of 131I therapy in the United States In: Boice JD, Fraumeni JF (eds) Radiation carcinogenesis. Raven Press, New York, pp 273–280
Kennedy RL, Kadlubowski M, Irvine WJ (1986) Graves thyrotoxicosis, autoantibodies and the response to radioactive iodine therapy. J Endocrinol [Suppl] 108:183 (abstr)
Lee GS, Sandler MP, Patton JA, Brill AB (1985) Serial thyroid iodine content in hyperthyroid patients treated with radioiodine. Clin Nucl Med 11:115–118
Shewring G, Smith BR (1982) An improved radioreceptor assay for TSH receptor antibodies. Clin Endocrinol 17:409–417
Toft AD, Hunter WM, Barnes EW, Seth J, Irvine WJ (1973) Raised plasma thyroid-stimulating-hormone levels in thyrotoxic patients treated with Iodine-131. Lancet ii:644–645
Tunbridge WMG, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA (1977) The spectrum of thyroid disease in a community. The Wickham Survey. Clin Endocrinol 7:481–493
Viherkoski M, Lambery BA, Herberg CA, Niemi E (1970) Treatment of toxic nodular goitre with radioactive iodine. Acta Endocrinol 64:159–170
Weetman AP, McGregor AM (1984) Autoimmune thyroid disease: Developments in our understanding. Endocrine Rev 5:309–355
Wilson R, McKillop JH, Pearson DW, Cuthbert GF, Thomson JA (1985) Relapse of Graves' disease after medical therapy: Predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels. J Nucl Med 26:1024–1928
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wilson, R., McKillop, J.H., Black, E. et al. Early prediction of hypotheroidism following 131I treatment for Graves' disease. Eur J Nucl Med 14, 180–183 (1988). https://doi.org/10.1007/BF00257324
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00257324